BioCardia, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
BioCardia, Inc. (BCDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 30.00 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-12
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 30.00K shares.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-12-31 was 11.80K shares.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2024-09-30 was 0.00 shares.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 321.80K shares, a 2049.06% increase from fiscal 2024.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 14.97K shares, a 68.29% decline from fiscal 2023.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 47.22K shares, a 92.68% decline from fiscal 2022.
- BioCardia, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 644.85K shares, a 16.52% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | 30.00K shares 10-Q · filed 2026-08-12 | |||||
| 2026-03-31 | 30.00K shares 10-Q · filed 2026-05-15 | ||||||
| 2025-12-31 | 321.80K shares 10-K · filed 2026-03-24 | ||||||
| 2024-12-31 | 11.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | 11.80K shares derived: sum of 2 quarters · filed 2026-03-24 | 14.97K shares 10-K · filed 2026-03-24 | ||||
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 3.18K shares 10-Q · filed 2024-11-13 | |||||
| 2024-06-30 | 3.18K shares 10-Q · filed 2024-08-13 | ||||||
| 2023-12-31 | -438.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | -496.29K shares derived: sum of 2 quarters · filed 2025-03-26 | 47.02K shares derived: sum of 3 quarters · filed 2025-03-26 | 47.22K shares 10-K · filed 2025-03-26 | 708.28K shares 10-K · filed 2024-03-27 | ||
| 2023-09-30 | -495.86K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-14 | 47.46K shares derived: sum of 2 quarters · filed 2024-05-14 | 47.66K shares 10-Q · filed 2024-05-14 | 543.51K shares 10-Q · filed 2023-11-08 | 88.56K shares derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2023-06-30 | 543.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 543.51K shares 10-Q · filed 2023-08-09 | 584.41K shares derived: sum of 3 quarters · filed 2023-08-09 | 683.42K shares derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2023-03-31 | 199.00 shares 10-Q · filed 2023-05-10 | 41.10K shares derived: sum of 2 quarters · filed 2023-05-10 | 140.10K shares derived: sum of 3 quarters · filed 2023-05-10 | 610.05K shares derived: sum of 4 quarters · filed 2023-05-10 | |||
| 2022-12-31 | 40.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 139.90K shares derived: sum of 2 quarters · filed 2023-03-29 | 609.85K shares derived: sum of 3 quarters · filed 2023-03-29 | 644.85K shares 10-K · filed 2023-03-29 | |||
| 2022-09-30 | 99.00K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 568.95K shares derived: sum of 2 quarters · filed 2022-11-09 | 603.95K shares 10-Q · filed 2022-11-09 | 603.95K shares derived: sum of 4 quarters · filed 2022-11-09 | |||
| 2022-06-30 | 469.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 504.95K shares 10-Q · filed 2022-08-10 | 504.95K shares derived: sum of 3 quarters · filed 2022-08-10 | 559.45K shares derived: sum of 4 quarters · filed 2022-08-10 | |||
| 2022-03-31 | 35.00K shares 10-Q · filed 2022-05-11 | 35.00K shares derived: sum of 2 quarters · filed 2022-05-11 | 89.50K shares derived: sum of 3 quarters · filed 2022-05-11 | 788.59K shares derived: sum of 4 quarters · filed 2022-05-11 | |||
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | 54.50K shares derived: sum of 2 quarters · filed 2022-03-29 | 753.59K shares derived: sum of 3 quarters · filed 2022-03-29 | 772.43K shares 10-K · filed 2022-03-29 | |||
| 2021-09-30 | 54.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 753.59K shares derived: sum of 2 quarters · filed 2021-11-10 | 772.43K shares 10-Q · filed 2021-11-10 | 814.24K shares derived: sum of 4 quarters · filed 2021-11-10 | |||
| 2021-06-30 | 699.09K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 717.93K shares 10-Q · filed 2021-08-12 | 759.74K shares derived: sum of 3 quarters · filed 2021-08-12 | 759.74K shares derived: sum of 4 quarters · filed 2021-08-12 | |||
| 2021-03-31 | 18.85K shares 10-Q · filed 2021-05-13 | 60.65K shares derived: sum of 2 quarters · filed 2021-05-13 | 60.65K shares derived: sum of 3 quarters · filed 2021-05-13 | 329.63K shares derived: sum of 4 quarters · filed 2021-05-13 | |||
| 2020-12-31 | 41.80K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-30 | 41.80K shares derived: sum of 2 quarters · filed 2021-03-30 | 310.78K shares derived: sum of 3 quarters · filed 2021-03-30 | 342.23K shares 10-K · filed 2021-03-30 | |||
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 268.98K shares derived: sum of 2 quarters · filed 2020-11-10 | 300.43K shares 10-Q · filed 2020-11-10 | 300.43K shares derived: sum of 4 quarters · filed 2020-11-10 | |||
| 2020-06-30 | 268.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | 300.43K shares 10-Q · filed 2020-08-13 | 300.43K shares derived: sum of 3 quarters · filed 2020-08-13 | 541.22K shares derived: sum of 4 quarters · filed 2020-08-13 | |||
| 2020-03-31 | 31.45K shares 10-Q · filed 2020-05-15 | 31.45K shares derived: sum of 2 quarters · filed 2020-05-15 | 272.24K shares derived: sum of 3 quarters · filed 2020-05-15 | ||||
| 2020-01-29 | 515.04K shares 10-K · filed 2022-03-29 | ||||||
| 2019-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-04-09 | 240.78K shares derived: sum of 2 quarters · filed 2020-04-09 | 254.78K shares 10-K · filed 2020-04-09 | ||||
| 2019-11-26 | 515.04K shares 10-Q · filed 2020-05-15 | ||||||
| 2019-09-30 | 240.78K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-19 | 254.78K shares 10-Q · filed 2019-11-19 | |||||
| 2019-06-30 | 14.00K shares 10-Q · filed 2019-08-14 | ||||||
| 2018-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-02 | 95.38K shares derived: sum of 2 quarters · filed 2019-04-02 | 269.38K shares derived: sum of 3 quarters · filed 2019-04-02 | 1.70M shares 10-K · filed 2019-04-02 | |||
| 2018-09-30 | 95.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | 269.38K shares derived: sum of 2 quarters · filed 2018-11-08 | 1.70M shares 10-Q · filed 2018-11-08 | 1.84M shares derived: sum of 4 quarters · filed 2018-11-08 | |||
| 2018-06-30 | 174.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | 1.60M shares 10-Q · filed 2018-08-09 | 1.74M shares derived: sum of 3 quarters · filed 2018-08-09 | -4.27M shares derived: sum of 4 quarters · filed 2018-08-09 | |||
| 2018-03-31 | 1.43M shares 10-Q · filed 2018-05-10 | 1.57M shares derived: sum of 2 quarters · filed 2018-05-10 | -4.44M shares derived: sum of 3 quarters · filed 2018-05-10 | -2.14M shares derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-12-31 | 137.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -5.87M shares derived: sum of 2 quarters · filed 2018-03-16 | -3.57M shares derived: sum of 3 quarters · filed 2018-03-16 | 842.65K shares 10-K · filed 2018-03-16 | |||
| 2017-09-30 | -6.01M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -3.71M shares derived: sum of 2 quarters · filed 2017-11-09 | 704.95K shares 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | 2.30M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | 6.71M shares 10-Q · filed 2017-08-14 | |||||
| 2017-03-31 | 4.41M shares 10-Q · filed 2017-05-11 | ||||||
| 2016-12-31 | 32.18M shares 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |